Deep 6 AI Announces Substantial Expansion Of Its Innovative AI-Based Clinical Trial Acceleration Software And Research Ecosystem
Deep 6 AI, the leader in artificial intelligence (AI)-based clinical trial acceleration software (CTAS), announced significant growth with the addition of key customer wins and an expanding executive leadership team. Experienced software and technology leaders Chris Brubaker and Talha F. Basit have joined the executive team as Chief Marketing and Customer Officer and Chief Technology Officer, respectively.
Recommended AI News: Spectra Offers Venues Universal Mobile Application Powered By Venuetize
“Our advanced, AI-based CTAS has the potential to change the clinical research landscape. My teammates and I believe that our product, technology, and data can truly impact patient lives and improve human health.”
“I started Deep 6 AI in 2016 to use the power of AI to rethink patient recruitment and trial feasibility in clinical research,” said Wout Brusselaers, CEO of Deep 6 AI. “Since then, we have worked to connect an entire ecosystem of sponsors, CROs, clinical researchers, physicians, and patients with the largest database of unstructured data in the industry in order to bring therapies to patients faster.”
With the recent addition of four additional health systems, the Deep 6 Ecosystem now contains:
- Dozens of leading research institutions including 6 NCI-designated comprehensive cancer centers
- 30,000 healthcare physicians and other providers
- 30 million patients
- Thousands of active trials
The ability to access and comprehend all patient data (structured and unstructured) across the multiple, disparate data systems in healthcare organizations is key as the importance of health data grows for research and quality healthcare purposes. Deep 6 AI’s CTAS supports trial feasibility assessments and patient recruitment using AI concepts including natural language processing (NLP) to precision match research criteria to patient characteristics, in minutes instead of months, resulting in fewer false positives, greater access to investigational treatments for patients, more successful trials, and faster time to market.
At the intersection of patient health, research, and big data, Deep 6 AI’s team brings together expertise from many different industries to collaborate within the health technology space. With the addition of two new members to the executive leadership team, the tradition of inter-industry innovation continues to shape the company’s approach to closing the gap between therapeutic development and patient care.
Recommended AI News: WhiteHat Security Announces Name Change To NTT Application Security
Talha F. Basit brings decades of expertise leading and growing engineering, data, and product teams for companies ranging from early-stage startups to large scale organizations. Most recently, Talha served as Chief Technology Officer for divvyDOSE, an online pharmacy that delivers personalized, presorted medication packs to patients. At divvyDOSE, Talha supported revenue growth from $1M to nearly $100M while building a state of the art cloud-enabled pharmacy operating system. That pharmacy operating system was the primary reason the divvyDOSE was acquired by UnitedHealth. Prior to divvyDOSE, Talha was the Chief Technology Officer for Dose Media LLC, where he helped secure $25M in Series B Funding. Previous roles include two tours at Apple Inc in Cupertino where he worked on the iMovie team.
As Deep 6 AI’s Chief Technology Officer, Talha will be responsible for the strategic direction and leadership of the engineering, data, machine learning, and product teams as they continue to innovate and build on the existing software.
“The opportunity to apply state of the art computer science, artificial intelligence, big data, and machine learning ideas to such an important arena as clinical trials was so compelling that I really had no choice but to join Deep 6 AI,” said Talha. “I look forward to working with a high caliber team to help bring treatments to the patients that need them the most and help defeat disease with data.”
Chris Brubaker is a marketing executive with extensive strategic experience leading software-as-a-service (SaaS) technology companies. Prior to joining Deep 6 AI, Chris was the Sr. Vice President of Marketing at Suki AI, a voice-based, AI digital assistant for physicians, where he led a complete rebrand, drove pipeline growth from $0 to nine figures in two years, and helped the company win numerous awards. Additional roles include Chief Marketing Officer for SLI Systems, and executive leadership roles at companies such as Upserve, Demandforce, and YouSendIt.
As Chief Marketing and Customer Officer, Chris will be responsible for translating Deep 6 AI’s business objectives into powerful stories that shape marketing perception and drive sales.
“This is an ideal time to join Deep 6 AI, and I couldn’t be more excited,” said Chris. “Our advanced, AI-based CTAS has the potential to change the clinical research landscape. My teammates and I believe that our product, technology, and data can truly impact patient lives and improve human health.”